Grazia Maria Vernaci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Grazia Maria Vernaci has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Maria Vittoria Dieci
Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy
30 shared publications - Gaia Griguolo
Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy
28 shared publications Marcello Lo Mele
26 shared publications- Tommaso Giarratano
Oncology 2, Veneto Institute of Oncology IOV IRCCS, Padova, Italy
26 shared publications Anna Tosi
21 shared publications- Antonino Musolino
Medical Oncology, Breast & GYN Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, 47014 Meldola, Italy
21 shared publications
Latest Publications
- Open Access
- 10 April 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (5)
Long-term outcome of isolated locoregional breast cancer recurrence: a large retrospective mono-institutional study
Background: Isolated locoregional relapse (ILRR) after curative treatment for early breast cancer (BC) is associated with poor prognosis. Treatment strategies are poorly standardized. We aimed at exploring prognostic factors and long-term outcomes of ILRR. Patients and methods: Overall, 1070 patients diagnosed with stage I-III BC between 2000 and 2007 were identified from a large mono-institutional dataset, with long follow up. Among these, 66 patients (6%) presented an ILRR as first BC event and 33% subsequently presented a distant recurrence (DR) (22/66). Results: In the overall study cohort, patients with ILRR presented a significantly higher risk of DR compared to those without ILRR (P < .001). However, while being diagnosed with a DR was significantly associated with a worse overall survival (OS), ILRR was not. In the subgroup of patients with ILRR (N = 66), more advanced nodal status at initial diagnosis and HER2-positivity on the ILRR were significantly associated with worse distant relapse-free interval (DRFI) post-ILRR and worse OS post-ILRR. Moreover, switching from HR+ primary BC to HR− ILRR was associated with worse OS post-ILRR. In multivariate analyses, nodal involvement at primary diagnosis remained independently associated with both DRFI and OS post-ILRR, while HER2+ ILRR was independently associated with worse OS post-ILRR. Conclusion: Patients diagnosed with ILRR after curative treatment for primary BC are at higher risk of subsequent DR, highlighting the need for prompt diagnosis and treatment of ILRR. Moreover, biological recharacterization of ILRR provides potential key prognostic and predictive factors, such as HR loss, allowing personalization of treatment and follow-up after ILRR.
- 10 April 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (5)
Open AccessLong-term outcome of isolated locoregional breast cancer recurrence: a large retrospective mono-institutional study
Background: Isolated locoregional relapse (ILRR) after curative treatment for early breast cancer (BC) is associated with poor prognosis. Treatment strategies are poorly standardized. We aimed at exploring prognostic factors and long-term outcomes of ILRR. Patients and methods: Overall, 1070 patients diagnosed with stage I-III BC between 2000 and 2007 were identified from a large mono-institutional dataset, with long follow up. Among these, 66 patients (6%) presented an ILRR as first BC event and 33% subsequently presented a distant recurrence (DR) (22/66). Results: In the overall study cohort, patients with ILRR presented a significantly higher risk of DR compared to those without ILRR (P < .001). However, while being diagnosed with a DR was significantly associated with a worse overall survival (OS), ILRR was not. In the subgroup of patients with ILRR (N = 66), more advanced nodal status at initial diagnosis and HER2-positivity on the ILRR were significantly associated with worse distant relapse-free interval (DRFI) post-ILRR and worse OS post-ILRR. Moreover, switching from HR+ primary BC to HR− ILRR was associated with worse OS post-ILRR. In multivariate analyses, nodal involvement at primary diagnosis remained independently associated with both DRFI and OS post-ILRR, while HER2+ ILRR was independently associated with worse OS post-ILRR. Conclusion: Patients diagnosed with ILRR after curative treatment for primary BC are at higher risk of subsequent DR, highlighting the need for prompt diagnosis and treatment of ILRR. Moreover, biological recharacterization of ILRR provides potential key prognostic and predictive factors, such as HR loss, allowing personalization of treatment and follow-up after ILRR.
- Open Access
- 24 April 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (14) , 2884-2894
Gene Expression Assays to Tailor Adjuvant Endocrine Therapy for HR+/HER2− Breast Cancer
Adjuvant endocrine therapy (ET) represents the standard of care for almost all hormone receptor (HR)+/HER2− breast cancers, and different agents and durations are currently available. In this context, the tailoring and optimization of adjuvant endocrine treatment by reducing unnecessary toxic treatment while taking into account the biological heterogeneity of HR+/HER2− breast cancer represents a clinical priority. There is therefore a significant need for the integration of biological biomarkers in the choice of adjuvant ET beyond currently used clinicopathological characteristics. Several gene expression assays have been developed to identify patients with HR+/HER2− breast cancer who will not derive benefit from the addition of adjuvant chemotherapy. By enhancing risk stratification and predicting therapeutic response, genomic assays have also shown to be a promising tool for optimizing endocrine treatment decisions. In this study, we review evidence supporting the use of most common commercially available gene expression assays [Oncotype DX, MammaPrint, Breast Cancer Index (BCI), Prosigna, and EndoPredict] in tailoring adjuvant ET. Available data on the use of genomic tests to inform extended adjuvant treatment choice based on the risk of late relapse and on the estimated benefit of a prolonged ET are discussed. Moreover, preliminary evidence regarding the use of genomic assays to inform de-escalation of endocrine treatment, such as shorter durations or omission, for low-risk patients is reviewed. Overall, gene expression assays are emerging as potential tools to further personalize adjuvant treatment for patients with HR+/HER2− breast cancers.
- 24 April 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (14) , 2884-2894
Open AccessGene Expression Assays to Tailor Adjuvant Endocrine Therapy for HR+/HER2− Breast Cancer
Adjuvant endocrine therapy (ET) represents the standard of care for almost all hormone receptor (HR)+/HER2− breast cancers, and different agents and durations are currently available. In this context, the tailoring and optimization of adjuvant endocrine treatment by reducing unnecessary toxic treatment while taking into account the biological heterogeneity of HR+/HER2− breast cancer represents a clinical priority. There is therefore a significant need for the integration of biological biomarkers in the choice of adjuvant ET beyond currently used clinicopathological characteristics. Several gene expression assays have been developed to identify patients with HR+/HER2− breast cancer who will not derive benefit from the addition of adjuvant chemotherapy. By enhancing risk stratification and predicting therapeutic response, genomic assays have also shown to be a promising tool for optimizing endocrine treatment decisions. In this study, we review evidence supporting the use of most common commercially available gene expression assays [Oncotype DX, MammaPrint, Breast Cancer Index (BCI), Prosigna, and EndoPredict] in tailoring adjuvant ET. Available data on the use of genomic tests to inform extended adjuvant treatment choice based on the risk of late relapse and on the estimated benefit of a prolonged ET are discussed. Moreover, preliminary evidence regarding the use of genomic assays to inform de-escalation of endocrine treatment, such as shorter durations or omission, for low-risk patients is reviewed. Overall, gene expression assays are emerging as potential tools to further personalize adjuvant treatment for patients with HR+/HER2− breast cancers.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
Supplementary Data from Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
Supplementary Data from Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
Supplementary Data from Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
Supplementary Data from Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
Supplementary Data from Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
Supplementary Data from Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
Supplementary Data from Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
Supplementary Data from Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
Supplementary Data from Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
Supplementary Data from Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
Supplementary Data from Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
Supplementary Data from Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
Supplementary Data from Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
Supplementary Data from Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial